Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. • Knowledge of marketing, strategic and long-range planning, training, and market access • Excellent communication and interpersonal skills, with the ability to collaborate effectively with internal and external stakeholders. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors.
Create an account to see the full posting, access our search engine, and more.